Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction

• US 8,603,462 B2
• Filed: 03/31/2004
• Issued: 12/10/2013
• Est. Priority Date: 04/01/2003
• Status: Expired due to Fees

• Current Assignee: University of Utah Research Foundation (State of Utah)
• Original Assignee: University of Utah Research Foundation (State of Utah), The United States of America As Represented By The Secretary of Agriculture
• Inventors: Westenfelder, Christof
• Primary Examiner(s): WEHBE, ANNE MARIE SABRINA
• Application Number:
  US10/551,317
• Publication Number:
  US 20070178071A1
• Time in Patent Office: 3,541 Days
• Field of Search: 424/93.7, 424/93.21, 435/372
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 38/195 Chemokines, e.g. RANTES
• CPC Class Codes: A61P 13/12 of the kidneys

Abstract

Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.

Claims

1. A method of treating acute renal failure, comprising delivering a single biologically and physiologically compatible solution containing a therapeutic amount of isolated human mesenchymal stem cells to a patient in need thereof, wherein the solution is not enriched for human pluripotent hematopoietic stem cells, wherein the therapeutic amount of human mesenchymal stem cells is between about 0.01 to about 5×

10⁶ mesenchymal stem cells per kilogram of patient weight, wherein the human mesenchymal stem cells are not co-administered with hematopoietic stem cells, wherein the patient suffers from or is at high risk of suffering from an acute deterioration in renal excretory function and wherein the mesenchymal stem cells are expanded in vitro to produce an enriched population of mesenchymal stem cells.

2. The method of claim 1 wherein said isolated mesenchymal stem cells comprise non-transformed stem cells.

3. The method of claim 1 wherein said isolated mesenchymal stem cells comprise genetically modified stem cells, wherein protective potency of said cells is augmented by genetic modification prior to administration in a patient in need thereof.

4. The method of claim 1 wherein said isolated mesenchymal stem cells comprise autologous cells.

5. The method of claim 1 wherein said isolated mesenchymal stem cells comprise allogeneic cells.

6. The method of claim 1, wherein the mesenchymal stem cells are isolated from bone marrow aspirates and adhere to the bottom of a culture dish while substantially all other cell types remain in suspension.